Current approaches for combination therapy of cancer: The role of immunogenic cell death.

Zahra Asadzadeh, Elham Safarzadeh, Sahar Safaei, Ali Baradaran, Ali Mohammadi, Khalil Hajiasgharzadeh, Afshin Derakhshani, Antonella Argentiero, Nicola Silvestris, Behzad Baradaran

Research output: Contribution to journalReview articlepeer-review


Cell death resistance is a key feature of tumor cells. One of the main anticancer therapies is increasing the susceptibility of cells to death. Cancer cells have developed a capability of tumor immune escape. Hence, restoring the immunogenicity of cancer cells can be suggested as an effective approach against cancer. Accumulating evidence proposes that several anticancer agents provoke the release of danger-associated molecular patterns (DAMPs) that are determinants of immunogenicity and stimulate immunogenic cell death (ICD). It has been suggested that ICD inducers are two different types according to their various activities. Here, we review the well-characterized DAMPs and focus on the different types of ICD inducers and recent combination therapies that can augment the immunogenicity of cancer cells.

Original languageEnglish
Article number1047
Issue number4
Publication statusPublished - Apr 2020


  • Combination therapy
  • DAMPs
  • Immunogenic cell death

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Current approaches for combination therapy of cancer: The role of immunogenic cell death.'. Together they form a unique fingerprint.

Cite this